PJT:NYSEPJT Partners Inc. Analysis
Data as of 2026-06-06 - not real-time
$157.22
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
PJT Partners posted a robust 28.9% revenue growth and maintains a gross margin of 95% with a 19% operating margin, underscoring the firm’s high‑profitability advisory model. Return on equity stands at an impressive 37%, while the forward P/E of 18.4 suggests earnings acceleration. However, the trailing P/E of 22.8 is well above the industry average of 17, and the price‑to‑book ratio of nearly 15 flags a premium valuation. A discounted cash‑flow analysis places fair value near $410, implying a material upside versus the current $157 price, though consensus analyst targets only imply an 8‑11% upside. Technical indicators show the stock trading above its 20‑day (155.6) and 50‑day (152.7) moving averages, with a bullish MACD crossover and a neutral RSI at 54, while support sits around $150 and resistance near $161. Recent news highlighted a modest insider sale by the CFO—the smallest in three years—providing limited downside pressure. The market sentiment index reads “Extreme Greed,” reflecting broader optimism that may sustain short‑term buying interest.
Given the blend of strong fundamentals, attractive upside potential, and stable technical backdrop, PJT appears positioned for continued outperformance. The modest insider sell‑off is unlikely to derail momentum, and the firm’s high ROE and cash generation support dividend sustainability despite a low 0.64% yield. Investors should monitor corporate‑deal flow trends and any macro‑economic shifts that could affect advisory demand, while considering a phased accumulation strategy to capitalize on the valuation gap.
Given the blend of strong fundamentals, attractive upside potential, and stable technical backdrop, PJT appears positioned for continued outperformance. The modest insider sell‑off is unlikely to derail momentum, and the firm’s high ROE and cash generation support dividend sustainability despite a low 0.64% yield. Investors should monitor corporate‑deal flow trends and any macro‑economic shifts that could affect advisory demand, while considering a phased accumulation strategy to capitalize on the valuation gap.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near short‑term resistance around $161
- Bullish MACD but neutral RSI
- Minor insider sell‑off limiting upside
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong revenue growth and high margins
- DCF fair value indicating substantial upside
- Bullish technical positioning above short‑term averages
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustainable high ROE and cash generation
- Resilient advisory franchise in a cyclical but profitable sector
- Undervaluation relative to intrinsic value and analyst targets
Key Metrics & Analysis
Financial Health
Revenue Growth28.90%
Profit Margin10.33%
P/E Ratio22.8
ROE37.04%
ROA21.94%
Debt/Equity45.34
P/B Ratio14.9
Op. Cash Flow$666.5M
Industry P/E17.0
Technical Analysis
TrendNeutral
RSI54.1
Support$150.01
Resistance$160.97
MA 20$155.61
MA 50$152.73
MA 200$164.43
MACDBullish
VolumeStable
Fear & Greed Index83.02
Valuation
Fair Value$410.32
Target Price$169.80
Upside/Downside8.00%
GradeUndervalued
TypeGrowth
Dividend Yield0.64%
Risk Assessment
Beta1.03
Volatility24.30%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.